Summary
The effects of verapamil and bendrofluazide used singly and in combination were examined in patients with primary hypertension in a patient blind, partly observer blind placebo controlled study of parallel group design; there were ten subjects in each arm of the trial.
Verapamil 160 mg twice daily caused supine mean arterial pressure to fall by 21 mm Hg; this reduction was significantly greater (p<0.05) than that induced by bendrofluazide 5 mg daily which caused a fall of only 10 mm Hg.
The addition of verapamil 160 mg twice daily to bendrofluazide 5 mg daily caused a further fall in pressure of 18 mm Hg (p<0.005), but the reduction in pressure when bendrofluazide was added to verapamil was only 1 mm Hg and not significant.
Bendrofluazide therapy caused a fall in plasma potassium concentration and an increase in plasma urate concentration; urinary calcium excretion was reduced. Verapamil caused no detectable biochemical alterations in plasma or urine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anavekar SN, Christophidis N, Louis WJ, Doyle AE (1981) Verapamil in the treatment of hypertension. J Cardiovasc Pharmacol 3: 287–292
Bing RF, Russell GI, Swales JD, Thurston H (1981) Indapamide and bendrofluazide: A comparison in the management of essential hypertension. Br J Clin Pharmacol 12: 883–886
Bühler FR, Hulthen UL, Kiowski W, Müller FB, Bolli P (1982) The place of the calcium antagonist verapamil in antihypertensive therapy. J Cardiovasc Pharmacol 4 [Suppl 3]: S350-S357
Cocco G, Iselin HU, Strozzi C, Cesana B, Baumeler HR (1987) Magnesium depletion in patients on long-term chlorthalidone therapy for essential hypertension. Eur J Clin Pharmacol 32: 335–338
Halperin AK, Gross KM, Rogers JF, Cubeddu LX (1984) Verapamil and propranolol in essential hypertension. Clin Pharmacol Ther 36: 750–758
Lehtonen A, Gordin A (1984) Metabolic parameters after changing from hydrochlorothiazide to verapamil treatment in hypertension. Eur J Clin Pharmacol 27: 153–157
Lewis GRJ, Morley KD, Lewis BM, Bones PJ (1978) The treatment of hypertension with verapamil. NZ Med J 87: 351–354
Lim P, Jacob E (1972) Magnesium deficiency in patients on long term diuretic therapy for heart failure. Br Med J 3: 620–624
MacGregor GA, Markando ND, Smith SJ, Sagnella GA (1985) Does nifedipine reveal a functional abnormality of arteriolar smooth muscle cell in essential hypertension — the effect of altering sodium balance. J Cardiovasc Pharmacol 7 [Suppl 6]: S178-S181
Medical Research Council Working Party (1985) M.R.C. trial of treatment of mild hypertension: Principal results. Br Med J 291: 97–104
Midtbø K, Hals O (1980) Verapamil in the treatment of hypertension. Curr Ther Res 27: 830–837
Rosei EA, Castellano M, Romanelli G, Beschi M, Fariello R, Alicandri C, Bianchini C, Muiesan G (1983) Haemodynamic and humoral changes during short and long-term treatment of essential hypertension with verapamil. J Hypertens 1: 375–378
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Benjamin, N., Phillips, R.J.W. & Robinson, B.F. Verapamil and bendrofluazide in the treatment of hypertension: A controlled study of effectiveness alone and in combination. Eur J Clin Pharmacol 34, 249–253 (1988). https://doi.org/10.1007/BF00540951
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00540951